Journal Information
Vol. 41. Issue 7.
Pages 446-447 (October 2017)
Vol. 41. Issue 7.
Pages 446-447 (October 2017)
Letter to the Editor
Full text access
Aspirin desensitization in patients with coronary artery disease: Cost savings
Desensibilización al ácido acetilsalicílico en pacientes con cardiopatía isquémica: ahorro de costes
J.L. Cuberoa,b,
Corresponding author

Corresponding author.
, B. Simó Sánchezc, P. Millánd, C. Colása,b
a Servicio de Alergia, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
b Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain
c Servicio de Cardiología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
d Servicio de Medicina Intensiva, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
This item has received
Article information
Full Text
Download PDF
Tables (2)
Table 1. Prices and treatment costs of the different antiplatelet drugs.
Table 2. Annual cost per patient of the dual antiplatelet drug combinations.
Show moreShow less
Full Text
Dear Sir,

Antiplatelet drugs play a key role in the management of ischemic heart disease and other diseases, exerting their effects though different pathways. The most useful of these drugs in application to coronary disease are the cyclooxygenase inhibitors: acetylsalicylic acid (ASA, aspirin), which is the most widely studied and used substance,1 and triflusal; and the P2Y12 antagonists: ticlopidine, clopidogrel, prasugrel and ticagrelor.

According to the current ischemic heart disease guides, in allergic patients were ASA is necessary, a rapid desensitization protocol must be applied,2 involving the administration of increasing doses of the drug until tolerance is achieved. Different rapid desensitization protocols have been described,3–5 with a duration of 2–5h, that can be used in unstable patients, with excellent efficacy and safety.

Despite the lack of clinical evidence to the effect (since no studies have suppressed the use of ASA), in patients who are hypersensitive to nonsteroidal antiinflammatory drugs and suffer confirmed chronic ischemic heart disease (detection of coronary atherosclerosis by computed axial tomography or positive ischemia testing), it is common to empirically prescribe triflusal or clopidogrel in monotherapy. In the event of percutaneous coronary intervention with the placement of a stent, even double-dose clopidogrel (or the prescription of prasugrel–ticagrelor) during one year has been used. In patients with acute coronary syndrome, dual antiplatelet treatment with triflusal and a P2Y12 inhibitor has been used on an empirical basis.

From the pharmacoeconomic perspective, ASA desensitization in patients with ischemic heart disease is comparatively less expensive in the context of both monotherapy and dual antiplatelet treatment (Tables 1 and 2).

Table 1.

Prices and treatment costs of the different antiplatelet drugs.

  Container price  Posology  Cost/day  Cost/month  Cost/year  Difference versus ASA 
ASA 100mg  1.45€/30tabl  100mg/day  0.048€  1.45€  17.64€  – 
Triflusal 300mg  5.53€/30tabl  600mg/day  0.369€  11.06€  134.56€  +662.76% 
Clopidogrel 75mg  16.81€/28tabl  75mg/day  0.600€  18.01€  219.13€  +1142.12% 
  30.02€/50tabl  150mg/day  1.201€  36.02€  438.26€  +2384.24% 
Ticlopidine 250mg  6.24€/20tabl  500mg/day  0.624€  18.72€  227.76€  +1191.03% 
Prasugrel 10mg  63.38€/28tabl  10mg/day  2.264€  67.91€  826.20€  +4583.25% 
Ticagrelor 90mg  89.61€/56tabl  180mg/day  3.200€  96.01€  1168.13€  +6521.43% 

Prices referred to Spain and updated in August 2016.

Table 2.

Annual cost per patient of the dual antiplatelet drug combinations.

  ASA  Triflusal  Clopidogrel  Ticlopidine  Prasugrel  Ticagrelor 
AAS  –  152.20€  236.77€  245.40€  845.84€  1185.77€ 
Triflusal  152.20€  –  353.69€  362.32€  962.76€  1302.69€ 
Clopidogrel  236.77€  353.69€  –  446.89€  1047.33€  1387.26€ 
Ticlopidine  245.40€  362.32€  446.89€  –  1055.96€  1395.89€ 
Prasugrel  845.84€  962.76€  1047.33€  1055.96€  –  1996.33€ 
Ticagrelor  1185.77€  1302.69€  1387.26€  1395.89€  1996.33€  – 

Prices referred to Spain and updated in August 2016.

In monotherapy, the annual cost of clopidogrel or triflusal is respectively 1142.12% (218.13 vs 17.64€) and 662.76% (134.56 vs 17.64€) greater than the cost of ASA. These differences could greatly increase (between 1408.05 and 3778.23%) in the case of treatment during the first 1–6months with prasugrel (cost between 266.02 and 515.52€) or ticagrelor (cost between 294.12 and 684.12€), followed by clopidogrel, as recommended by some guides.2

At present, the only dual antiplatelet treatment protocol recommended by the current guides is ASA plus a P2Y12 inhibitor.2 As a result, in patients allergic to ASA, desensitization to the latter drug is indicated for correct treatment, and this is moreover the least expensive option (Table 2). As an example, ASA plus clopidogrel has an annual cost per patient of 236.77€, which is far lower than in the case of the rest of the possible dual antiplatelet treatment combinations.

In conclusion, ASA is the option with the greatest supporting clinical evidence and lowest cost for the treatment of ischemic heart disease. Acetylsalicylic acid desensitization is required in patients who are allergic to the drug, indistinctly of whether it is prescribed as monotherapy or in the context of dual antiplatelet treatment. Close coordination is required among the Departments of Allergic Diseases, Cardiology and Intensive Care Medicine in order to develop protocols adapted to the needs of each center, with a view to optimizing the management of these patients.

J. Taylor.
Primary prevention of coronary artery disease by aspirin.
Eur Heart J, 36 (2015), pp. 467-468
S. Windecker, P. Kolh, F. Alfonso, J.P. Collet, J. Cremer, V. Falk, et al.
2014 ESC/EACTS guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
Eur Heart J, 35 (2014), pp. 2541-2619
G. Dalmau, P. Gaig, V. Gázquez, J. Mercé.
Desensibilización rápida al ácido acetilsalicílico en pacientes con intolerancia a AINE afectos de síndrome coronario agudo.
Rev Esp Cardiol, 62 (2009), pp. 224-225
P. Díez-Villanueva, P. Antuña, M.V. Múgica, M.T. Belver, R. Aguilar, F. Alfonso.
Desensibilización a la aspirina en pacientes con síndrome coronario agudo.
Med Intensiva, 40 (2016), pp. 452-454
M. Bianco, A. Bernardi, F. D’Ascenzo, E. Cerrato, P. Omedè, A. Montefusco, et al.
Efficacy and safety of available protocols for aspirin hypersensitivity for patients undergoing percutaneous coronary intervention: a survey and systematic review.
Circ Cardiovasc Interv, 9 (2016), pp. e002896

Please cite this article as: Cubero JL, Simó Sánchez B, Millán P, Colás C. Desensibilización al ácido acetilsalicílico en pacientes con cardiopatía isquémica: ahorro de costes. Med Intensiva. 2017;41:446–447.

Copyright © 2016. Elsevier España, S.L.U. and SEMICYUC
Medicina Intensiva (English Edition)
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?